Octreotate-Lu-177-DOTA-Tyr-3

Octreotate-Lu-177-DOTA-Tyr-3 Reactions 1680, p263 - 2 Dec 2017 Thrombocytopenia: case report In a retrospective cohort analysis of 167 patients, a patient [age and sex not stated] was described, who developed thrombocytopenia during treatment with octreotate- Lu-177-DOTA-Tyr-3 [ Lu-DOTATATE; duration of treatment to reaction onset not stated]. The patient, who had advanced neuroendocrine tumour, received treatment with 5550 to 7400 MBq (150 200 mCi) of octreotate-Lu-177-DOTA-Tyr-3 diluted in 48 to 50mL of sodium chloride [saline] and infused over 30 minutes with a flow rate of 1.6 mL/minute. The patient received octreotate- Lu-177-DOTA-Tyr-3 after 30 to 60 minutes from the start of amino acid infusion. Before the initiation of treatment, the patient had grade I thrombocytopenia. However, during the course of therapy, the patient exhibited further depletion in the platelet counts (86000 48000 /µL), which was considered as grade III thrombocytopenia. The patient’s decreased platelet count was managed with platelet transfusion. Author comment: "Treatment-related adverse events were analyzed in all the patients." "One patient presented with grade I thrombocytopenia at the time of recruitment and progressed to grade III toxicity." "The platelet counts in this patient were revived through platelet transfusion." Ballal S, et al. Concomitant 177Lu-DOTATATE and Capecitabine Therapy in Patients with Advanced Neuroendocrine Tumors: A Long-term-Outcome, Toxicity, Survival, and Quality-of-Life Study. Clinical Nuclear Medicine 42: e457-e466, No. 11, Nov 2017. Available from: URL: http://doi.org/10.1097/ RLU.0000000000001816 - India 803284431 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Octreotate-Lu-177-DOTA-Tyr-3

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/octreotate-lu-177-dota-tyr-3-xw4GQomurB
Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39194-0
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p263 - 2 Dec 2017 Thrombocytopenia: case report In a retrospective cohort analysis of 167 patients, a patient [age and sex not stated] was described, who developed thrombocytopenia during treatment with octreotate- Lu-177-DOTA-Tyr-3 [ Lu-DOTATATE; duration of treatment to reaction onset not stated]. The patient, who had advanced neuroendocrine tumour, received treatment with 5550 to 7400 MBq (150 200 mCi) of octreotate-Lu-177-DOTA-Tyr-3 diluted in 48 to 50mL of sodium chloride [saline] and infused over 30 minutes with a flow rate of 1.6 mL/minute. The patient received octreotate- Lu-177-DOTA-Tyr-3 after 30 to 60 minutes from the start of amino acid infusion. Before the initiation of treatment, the patient had grade I thrombocytopenia. However, during the course of therapy, the patient exhibited further depletion in the platelet counts (86000 48000 /µL), which was considered as grade III thrombocytopenia. The patient’s decreased platelet count was managed with platelet transfusion. Author comment: "Treatment-related adverse events were analyzed in all the patients." "One patient presented with grade I thrombocytopenia at the time of recruitment and progressed to grade III toxicity." "The platelet counts in this patient were revived through platelet transfusion." Ballal S, et al. Concomitant 177Lu-DOTATATE and Capecitabine Therapy in Patients with Advanced Neuroendocrine Tumors: A Long-term-Outcome, Toxicity, Survival, and Quality-of-Life Study. Clinical Nuclear Medicine 42: e457-e466, No. 11, Nov 2017. Available from: URL: http://doi.org/10.1097/ RLU.0000000000001816 - India 803284431 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off